Share this article on:

Non-small cell lung cancer: Recent advances

doi: 10.1097/01.NURSE.0000441878.64877.76
CE Connection

For more than 74 additional continuing education articles related to cancer topics, go to

Earn CE credit online: Go to and receive a certificate within minutes.

Back to Top | Article Outline

INSTRUCTIONS Non-small cell lung cancer: Recent advances


  • To take the test online, go to our secure website at
  • On the print form, record your answers in the test answer section of the CE enrollment form on page 43. Each question has only one correct answer. You may make copies of these forms.
  • Complete the registration information and course evaluation. Mail the completed form and registration fee of $24.95 to: Lippincott Williams & Wilkins, CE Group, 74 Brick Blvd., Bldg. 4, Suite 206, Brick, NJ 08723. We will mail your certificate in 4 to 6 weeks. For faster service, include a fax number and we will fax your certificate within 2 business days of receiving your enrollment form.
  • You will receive your CE certificate of earned contact hours and an answer key to review your results. There is no minimum passing grade.
  • Registration deadline is February 29, 2016.
Back to Top | Article Outline


  • Send two or more tests in any nursing journal published by Lippincott Williams & Wilkins together by mail, and deduct $0.95 from the price of each test.
  • We also offer CE accounts for hospitals and other healthcare facilities on Call 1-800-787-8985 for details.
Back to Top | Article Outline


Lippincott Williams & Wilkins, publisher of Nursing2014 journal, will award 2.8 contact hours for this continuing nursing education activity.

Lippincott Williams & Wilkins is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

Lippincott Williams & Wilkins is also an approved provider of continuing nursing education by the District of Columbia and Florida #50–1223. This activity is also provider approved by the California Board of Registered Nursing, Provider Number CEP 11749 for 2.8 contact hours.

Your certificate is valid in all states. This activity has been assigned .5 pharmacology credits.

The ANCC's accreditation status of Lippincott Williams & Wilkins Department of Continuing Education refers only to its continuing nursing educational activities and does not imply Commission on Accreditation approval or endorsement of any commercial product.

Non-small cell lung cancer: Recent advances

GENERAL PURPOSE: To provide nurses with the most recent information about non-small cell lung cancer (NSCLC). LEARNING OBJECTIVES: After reading this article and taking this test, you should be able to: 1. Identify the risk factors associated with NSCLC. 2. Differentiate the surgical approaches used to treat patients with NSCLC. 3. Discuss nursing considerations for patients with NSCLC.

  1. Which group has the highest incidence and death rates from lung cancer?
    1. White women
    2. Black males
    3. Hispanic women
    4. Asian males
  2. Most lung cancers are seen in patients over age
    1. 35.
    2. 45.
    3. 50.
    4. 60.
  3. Patients with nonsmoking-associated lung cancer tend to be
    1. Asian.
    2. older.
    3. men.
    4. women.
  4. Which statement best describes the screening tests specific for lung cancer?
    1. They're expensive.
    2. They have low false-negative rates.
    3. They have high false-positive rates.
    4. There are none.
  5. Common signs of NSCLC include
    1. hematuria.
    2. repeated bronchial infections.
    3. rash.
    4. fever.
  6. Signs of metastasized NSCLC include all of the following except
    1. a lump in one breast.
    2. jaundice.
    3. bone pain.
    4. enlarged lymph nodes.
  7. When hormone-like substances produced by a tumor affect distant tissues or organs, it's called
    1. superior vena cava syndrome.
    2. DiGeorge syndrome.
    3. paraneoplastic syndromes.
    4. Horner syndrome.
  8. The diagnostic imaging test of choice for evaluating patients with a potential lung cancer diagnosis is a chest
    1. X-ray.
    2. CT.
    3. MRI.
    4. ultrasound.
  9. Which lung cancer stage is also called carcinoma in situ?
    1. Stage 0
    2. Stage I
    3. Stage II
    4. Stage III
  10. The gold standard of lymph node evaluation and testing for a patient with NSCLC is
    1. bronchoscopy.
    2. mediastinoscopy.
    3. vascular ultrasonography.
    4. pulmonary angiography.
  11. Wedge resection of the lung involves removal of
    1. the entire affected lung.
    2. part of one lung lobe.
    3. one lung lobe.
    4. the tumor and an area of the lung around the tumor.
  12. In the first few hours after surgery, the surgeon should be notified of chest tube drainage exceeding
    1. 50 mL/hour.
    2. 100 mL/hour.
    3. 200 mL/hour.
    4. 250 mL/hour.
  13. A change in the color of chest tube drainage to milky white may indicate a (an)
    1. pneumonia.
    2. empyema.
    3. chyle leak.
    4. hemothorax.
  14. After surgery, which assessment finding indicates an air leak into the subcutaneous tissue from the pleural space?
    1. pursed lip breathing
    2. tripod positioning
    3. tissue that feels like crunchy rice cereal
    4. tachypnea
  15. Following a thoracotomy, pericardial inflammation frequently causes
    1. sinus bradycardia.
    2. heart block.
    3. premature ventricular contractions.
    4. atrial fibrillation.
  16. Radiation therapy using stereotactic approaches is often used for which stage of NSCLC?
    1. operable Stage I
    2. nonoperable Stage I
    3. operable Stage II
    4. nonoperable Stage II
  17. The standard chemotherapy treatment for NSCLC is
    1. cisplatin.
    2. etoposide.
    3. gemcitabine.
    4. pemetrexed.
  18. Which therapy can best assist a patient with NSCLC who has a feeling of air hunger at the end of life?
    1. hyperbaric oxygen therapy
    2. continuous positive airway pressure
    3. opioids
    4. mechanical ventilation


© 2014 by Wolters Kluwer Health | Lippincott Williams & Wilkins.